Bank Hapoalim BM’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.78M | Buy |
19,640
+130
| +0.7% | +$10.9K | 0.12% | 60 |
|
|
2026
Q1 | $1.56M | Buy |
19,510
+450
| +2% | +$37.1K | 0.24% | 54 |
|
|
2025
Q4 | $1.63M | Sell |
19,060
-90
| -0.5% | -$7.39K | 0.14% | 59 |
|
|
2025
Q3 | $1.49M | Sell |
19,150
-11,250
| -37% | -$879K | 0.18% | 64 |
|
|
2025
Q2 | $2.38M | Sell |
30,400
-60
| -0.2% | -$4.47K | 0.32% | 53 |
|
|
2025
Q1 | $2.21M | Buy |
30,460
+2,120
| +7% | +$152K | 0.32% | 54 |
|
|
2024
Q4 | $2.1M | Sell |
28,340
-1,125
| -4% | -$78.7K | 0.34% | 54 |
|
|
2024
Q3 | $1.94M | Hold |
29,465
| – | – | 0.29% | 63 |
|
|
2024
Q2 | $2.72M | Sell |
29,465
-2,500
| -8% | -$221K | 0.38% | 57 |
|
|
2024
Q1 | $3.06M | Buy |
31,965
+19,565
| +158% | +$1.64M | 0.4% | 55 |
|
|
2023
Q4 | $946K | Buy |
12,400
+5,500
| +80% | +$383K | 0.13% | 93 |
|
|
2023
Q3 | $478K | Buy |
6,900
+700
| +11% | +$56.3K | 0.08% | 105 |
|
|
2023
Q2 | $585K | Hold |
6,200
| – | – | 0.08% | 120 |
|
|
2023
Q1 | $513K | Sell |
6,200
-50
| -0.8% | -$3.93K | 0.07% | 134 |
|
|
2022
Q4 | $466K | Sell |
6,250
-500
| -7% | -$38.5K | 0.06% | 140 |
|
|
2022
Q3 | $558K | Buy |
6,750
+299
| +5% | +$28.8K | 0.07% | 134 |
|
|
2022
Q2 | $613K | Buy |
6,451
+1,201
| +23% | +$124K | 0.08% | 138 |
|
|
2022
Q1 | $618K | Sell |
5,250
-2,015
| -28% | -$226K | 0.06% | 150 |
|
|
2021
Q4 | $941K | Sell |
7,265
-260
| -3% | -$30.3K | 0.09% | 136 |
|
|
2021
Q3 | $852K | Hold |
7,525
| – | – | 0.09% | 137 |
|
|
2021
Q2 | $779K | Buy |
7,525
+400
| +6% | +$37.7K | 0.09% | 144 |
|
|
2021
Q1 | $596K | Hold |
7,125
| – | – | 0.08% | 148 |
|
|
2020
Q4 | $650K | Sell |
7,125
-1,450
| -17% | -$120K | 0.09% | 126 |
|
|
2020
Q3 | $684 | Sell |
8,575
-743
| -8% | -$58K | 0.03% | 100 |
|
|
2020
Q2 | $644K | Sell |
9,318
-51
| -0.5% | -$3.62K | 0.15% | 104 |
|
|
2020
Q1 | $589K | Buy |
9,369
+225
| +2% | +$16.2K | 0.19% | 90 |
|
|
2019
Q4 | $711K | Buy |
9,144
+1,113
| +14% | +$86.9K | 0.16% | 88 |
|
|
2019
Q3 | $582K | Hold |
8,031
| – | – | 0.14% | 95 |
|
|
2019
Q2 | $495K | Buy |
8,031
+681
| +9% | +$41.2K | 0.12% | 109 |
|
|
2019
Q1 | $469K | Sell |
7,350
-3,030
| -29% | -$173K | 0.11% | 106 |
|
|
2018
Q4 | $530K | Sell |
10,380
-1,359
| -12% | -$68.8K | 0.17% | 94 |
|
|
2018
Q3 | $681K | Buy |
11,739
+549
| +5% | +$26.9K | 0.17% | 99 |
|
|
2018
Q2 | $543K | Buy |
11,190
+1,050
| +10% | +$49K | 0.15% | 122 |
|
|
2018
Q1 | $472K | Sell |
10,140
-13,725
| -58% | -$596K | 0.12% | 118 |
|
|
2017
Q4 | $897 | Buy |
23,865
+2,850
| +14% | +$105K | 0.2% | 86 |
|
|
2017
Q3 | $766K | Buy |
+21,015
| New | +$801K | 0.17% | 103 |
|
Other funds holding EW
WT
Bank Hapoalim BM's EW Position: Q2 2026 in Review
Bank Hapoalim BM increased its Edwards Lifesciences (EW) stake by 0.67% in Q2 2026, buying an estimated $10.9K and bringing the position to 19,640 shares worth $1.78M. The position accounts for 0.12% of the portfolio, ranked #60.
Bank Hapoalim BM first reported a position in EW in Q3 2017 and has held it in 36 quarters since. The position peaked at $3.06M in Q1 2024. 733 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Bank Hapoalim BM held 19,640 shares of Edwards Lifesciences worth $1.78M as of Q2 2026.
- Bank Hapoalim BM bought 130 Edwards Lifesciences shares in Q2 2026, an estimated $10.9K.
- Edwards Lifesciences made up 0.12% of Bank Hapoalim BM's portfolio in Q2 2026, its #60 holding.
- Bank Hapoalim BM first reported a position in Edwards Lifesciences in Q3 2017 and has held it in 36 quarters since.
- Bank Hapoalim BM's Edwards Lifesciences position peaked at $3.06M in Q1 2024.
- 733 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Bank Hapoalim BM's 13F filing for Q2 2026, filed 5 Aug 2026.